- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
A RAVE Upgrade: Previewing Revolutionizing Alopecia Areata, Vitiligo, and Eczema
Jonathan Silverberg, MD, PhD, MPH, shares insights into the change of this year’s meeting and the benefit of additional disease states.
“Over the years, we've queried our audience members of RAD and said, ‘Do you like the meeting?’ They said, ‘Yes, we love it.’ We asked, ‘What else would you like to learn about?’ There was an overwhelming call for taking a deep dive into alopecia areata and vitiligo, just given all of the amazing innovation,” said Jonathan Silverberg, MD, PhD, MPH, in an interview with Dermatology Times discussing the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) conference, held in Chicago, Illinois.
Silverberg, the chair of the Revolutionizing Atopic Dermatitis (RAD) portion of RAVE and professor of dermatology and director of clinical research and contact dermatitis at the George Washington University School of Medicine and Health Sciences in Washington, DC, spoke with Dermatology Times to preview the exciting new Revolutionizing Alopecia Areata, Vitiligo, and Eczema conference and how the 2 additional disease states will best serve clinicians treating multiple inflammatory conditions among their patients.
According to Silverberg, it is imperative for dermatologists, immunologists, and anyone who is treating inflammatory skin conditions to keep up with all of the latest data, drug approvals, and innovations in dermatology.
“There's a lot that we treat in dermatology, and we want to be able to provide top tier education for all disorders,” said Silverberg.
Regarding the change from the annual RAD meeting to the new inaugural RAVE meeting, Silverberg noted that RAVE has “something for everyone.” To best serve clinicians, topics across all disease states will cover complexities around diagnoses, addressing environmental factors across the different disorders, recognizing different treatment modalities, how to optimize traditional therapies, and understanding how to incorporate the new therapeutics into the management of inflammatory skin conditions.
“RAVE is going to be jam-packed with outstanding content that the audience can really trust in terms of being evidence-based and high quality information. But it's also going to be a lot of fun; perhaps the name 'RAVE’ gives away that we are not the typical boring conference,” concluded Silverberg.
For live daily email updates from RAVE, subscribe to our eNewsletter.
